Metal-free and MRI visible theranostic lyotropic liquid crystal nitroxide-based nanoparticles

Muir, Benjamin W.; Acharya, Durga P.; Kennedy, Danielle F.; Mulet, Xavier; Evans, Richard A.; Pereira, Suzanne M.; Wark, Kim L.; Boyd, Ben J.; Nguyen, Tri‐Hung; Hinton, Tracey M.; Waddington, Lynne J.; Kirby, Nigel; Wright, David K.; Wang, Hong X.; Egan, Gary F.; Moffat, Bradford A.

doi:10.1016/j.biomaterials.2011.12.018

Cited by 79 publications

(85 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The r 1 or spin‐lattice relaxivity values for the samples in the current study were found to be the highest at the lowest concentration of Gd employed within the silicates ( Figure ), 20.60 s −1 mM −1 for EuGd_150_01_05 with 0.2 mM Gd. A maximum in r 1 for nanoparticulate CAs with low sub mM paramagnetic doping has also been reported by various other researchers 8a,b, 34, 36. The spin‐spin relaxivity in the gadolinosilicates also exhibits a maximum at low Gd dopant (Figure 6b).…”

Section: Resultssupporting

confidence: 82%

Mesoporous Europo‐Gadolinosilicate Nanoparticles as Bimodal Medical Imaging Agents and a Potential Theranostic Platform

Tse

Kennedy

Kirby

et al. 2013

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

The mesoporous structure of sol-gel prepared gadolinium and europium doped silicate nanoparticles has been found to be highly dependent on the formulated composition, with synthesised samples displaying both disordered and hexagonally ordered mesoporous packing symmetry. The degree of pore ordering within the nanoparticles has a strong correlation with the total lanthanide (Gd(3+) and Eu(3+) ) concentration. The gadolinosilicates are excellent magnetic resonance imaging (MRI) longitudinal (T1 ) agents. The longitudinal relaxivity (r1 ) and transverse (r2 ) relaxivity, a measure of MRI contrast agent efficiency, were up to four times higher than the clinically employed Omniscan (gadodiamide); with r1 up to 20.6 s(-1) mM(-1) and r2 of 66.2 s(-1) mM(-1) compared to 5.53 and 4.64 s(-1) mM(-1) , respectively, for Omniscan. In addition, the europium content of all the samples studied is below the self-quenching limit, which results in a strong luminescence response from the nanoparticles on excitation at 250 nm. The Eu-Gd silicate nanoparticles act as bimodal imaging agents for MRI and luminescence. These mesoporous nanoparticles also have the potential to serve as encapsulation and controlled release matrices for pharmaceuticals. They are therefore a promising multimodal theranostic platform.

show abstract

Section: Resultssupporting

confidence: 82%

Mesoporous Europo‐Gadolinosilicate Nanoparticles as Bimodal Medical Imaging Agents and a Potential Theranostic Platform

Tse

Kennedy

Kirby

et al. 2013

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…The future developments for the stabilization of cubosomes involve adding functionalization (i.e., targeting and MRI imaging agent) to the stabilizer, for active targeting capabilities [92,93,106,108,188]. An extensive review of cubosome targeting, drug delivery, and medical imaging was recently written by Mulet et al [106].…”

Section: Future Developments In the Stabilization Of Cubosomesmentioning

confidence: 98%

“…In other recent developments, cubosomes are also being investigated for the containment of contrast agents for medical imaging applications [106][107][108], and capabilities as a cell-free bio-sensing platform [109]. Apart from drug delivery and biomedical applications, the use and application of lyotropic liquid crystalline nanostructured particles is also relevant within the food industry (e.g., solubilization of food bioactives within lyotropic liquid crystalline mesophases) [110,111] and agriculture industry (e.g., delivery of plant agrochemicals) [112].…”

Section: Applications Of Cubosomes In Nanotechnologymentioning

confidence: 99%

Steric Stabilizers for Cubic Phase Lyotropic Liquid Crystal Nanodispersions (Cubosomes)

Chong

Mulet

Boyd

et al. 2015

Advances in Planar Lipid Bilayers and Liposomes

Self Cite

View full text Add to dashboard Cite

“…1 In recent years there have been several studies reporting on nano medicinal applications of Lyotropic liquid crystalline (LLC) phases like in development of novel contrast enhancers for magnetic resonance imaging (MRI). 2,3 Within the food and pharmaceutical research, LLC nano materials have shown potentials in the development of novel delivery systems. [4][5][6] These nanostructures are self-assemblies of naturally occurring surfactantlike lipid molecules which are closely related to those observed in biological membranes and empower the formation of efficient delivery matrices due to their impressive characteristics:…”

Section: Introductionmentioning

confidence: 99%

Lyotropic Liquid Crystalline Phases for the Formulation of Future Functional Foods

Sadeghpour¹

2016

JNHFE

View full text Add to dashboard Cite

The especial features and advanced characteristics of Lyotropic Liquid Crystalline (LLC) phases as potent nano materials for encapsulation and the development of novel delivery systems for nutraceuticals and other bioactive compounds are reviewed. Exemplary, a focus is set on the health benefits of flavonoids and their current restrictions in bioavailability. Accordingly, our visions for application of LLC phases in the engineering of enhanced flavonoid-based food supplements and correlated challenges to overcome are highlighted.

show abstract

Metal-free and MRI visible theranostic lyotropic liquid crystal nitroxide-based nanoparticles

Cited by 79 publications

References 51 publications

Mesoporous Europo‐Gadolinosilicate Nanoparticles as Bimodal Medical Imaging Agents and a Potential Theranostic Platform

Mesoporous Europo‐Gadolinosilicate Nanoparticles as Bimodal Medical Imaging Agents and a Potential Theranostic Platform

Steric Stabilizers for Cubic Phase Lyotropic Liquid Crystal Nanodispersions (Cubosomes)

Lyotropic Liquid Crystalline Phases for the Formulation of Future Functional Foods

Contact Info

Product

Resources

About